Pneumococcal seroepidemiology in Turkey: Implications for vaccine coverage

Erdem H., ŞENER B.

VACCINE, vol.26, no.10, pp.1271-1273, 2008 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Letter
  • Volume: 26 Issue: 10
  • Publication Date: 2008
  • Doi Number: 10.1016/j.vaccine.2007.12.036
  • Journal Name: VACCINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1271-1273
  • Hacettepe University Affiliated: Yes

Abstract

This paper aims to bring up the most prevalent pneumococcal. serotypes and serogroups detected in recent Turkish studies. The current PCV-7 formulation covers only 37% of IPI in Turkey and if serotypes /groups 4, 6V, 9B, 18C in the current formulation are replaced with 1, 3, 6B and 9A in PCV-7, then the vaccination coverage will increase up to 64%, an improvement that is significant statistically. Similarty, if 11 A, 12F, 1513, 17F and 22F are substituted with 6A, 9A, 9L, 19C and 23B in existing PPV-23, the new formulation wilt increase coverage up to 95% for Turkish population. (C) 2007 Elsevier Ltd. AU rights reserved.